Flagship Biosciences

Flagship Biosciences

Flagship Biosciences was founded in 2009 as a technology-driven spatial biology and biomarker services company, serving pharmaceutical and biotech clients. The firm is led by a scientific management team including Thomas Turi, Ph.D., Boaz Kurtis, MD, and other board-certified pathologists. It operates as a CLIA-Certified and CAP-Accredited laboratory, not a family office or asset manager. The company provides clinical trial support across three core service lines: spatial biology (IHC to digital spatial profiling), genomics (high-throughput NGS and targeted gene panels), and histopathology with AI analysis. Clients include neuro-oncology laboratories, biopharma directors, and a global oncology research database provider. The firm emphasizes AI-powered analysis to reduce variability in drug development and diagnostics. Flagship Biosciences is headquartered in Broomfield, Colorado, with no disclosed additional offices. The leadership team is composed of scientists and medical doctors, with no publicly listed investment professionals or AUM. No recent operational events from the last 24 months were found in public sources. A structural differentiator is its dual role as both a laboratory service provider and an AI-driven data analysis partner, combining CAP-CLIA certification with machine learning capabilities. This hybrid model allows it to support both clinical trials and translational research within a single regulated environment.